Ki67 for evaluating the prognosis of gastrointestinal stromal tumors: A systematic review and meta‑analysis

Li, Ji; Wang, An-Ran; Chen, Xiao; Pan, Hong; Li, Shi-Qiang

doi:10.3892/ol.2022.13309

Cited by 13 publications

(8 citation statements)

References 55 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Ki-67 index can serve as an important reference for evaluating the tumor risk classification. A close relationship between the expression level of Ki-67 and the prognosis of GIST was also identified in a large-sample meta-analysis, with a higher rate of Ki-67 related to worse patient prognosis (29); this is consistent with our main findings. Another large-sample retrospective analysis found that the prognosis of high-risk patients with high Ki-67 expression was significantly worse than that of patients with low Ki-67 expression (30).…”

Section: Discussionsupporting

confidence: 91%

The relationship between Ki-67 expression and imaging signs and pathological features in GISTs

Xiao

Zhang²,

Wang³

et al. 2023

Front. Surg.

View full text Add to dashboard Cite

IntroductionTo investigate the correlations between the Ki-67 index and plain-scan computerized tomography (CT) signs and pathological features of gastrointestinal stromal tumor (GIST) tissue.Materials and methodsData from 186 patients with GIST diagnosed by pathology and immunohistochemistry (IHC) in Peking University First Hospital from May 2016 to May 2022 were analyzed. The patients were divided into two groups: Ki-67 ≤5% and >5%. Correlation analysis, univariate and multivariate Logistic regression analysis were used to explore the correlations between CT signs, pathological features, and Ki-67 expression.ResultsUnivariate indicators correlated with the Ki-67 index were mitotic count, pathological grade, tumor hemorrhage, tumor necrosis, tumor size, and tumor density. Multivariate Logistic regression indicated that the mitotic count [odds ratio (OR) 10.222, 95% confidence interval (CI) 4.312–31.039], pathological grade (OR 2.139, 95% CI 1.397–3.350), and tumor size (OR 1.096, 95% CI 1.020–1.190) were independently associated with the Ki-67 expression level. The concordance indexes (C-index) for the pathological features and CT signs models were 0.876 (95% CI 0.822–0.929) and 0.697 (95% CI 0.620–0.774), respectively, with positive predictive values of 93.62% and 58.11% and negative predictive values of 81.29% and 75.89%, respectively. After internal verification by the Bootstrap method, the fitting degree of the pathological features model was found to be better than that of the CT signs model.ConclusionMitotic count, pathological risk grading, and tumor size are independent risk factors correlating with high Ki-67 index. These results indicate that the Ki-67 index reflects tumor malignancy and can predict recurrence and metastasis of GIST.

show abstract

Section: Discussionsupporting

confidence: 91%

The relationship between Ki-67 expression and imaging signs and pathological features in GISTs

Xiao

Zhang²,

Wang³

et al. 2023

Front. Surg.

View full text Add to dashboard Cite

show abstract

“…The expression of Ki67 is strongly associated with tumor cell proliferation and growth and has been widely used in the assessment of tumors. , Here, Ki67 protein levels decreased significantly in tumor tissues from the N1 -lighted and NG2 -lighted groups, as well as those in tumor tissues from the N-cRGD -lighted and NG-cRGD -lighted groups, which further verified their antiproliferative activity (Figure G). Furthermore, hematoxylin and eosin (H&E) staining of tumor tissues revealed prominent cell death in the N1 -lighted, NG2 -lighted, N-cRGD -lighted, and NG-cRGD -lighted groups displaying their in vivo antitumor activity with light illumination, while no obvious cell damage was observed in the control groups (Figure H).…”

Section: Resultssupporting

confidence: 60%

Self-Immolative Photosensitizers for Self-Reported Cancer Phototheranostics

Wang¹,

Sun²,

Huang³

et al. 2023

J. Am. Chem. Soc.

View full text Add to dashboard Cite

Photosensitizers to precise target and change fluorescence upon light illumination could accurately self-report where and when the photosensitizers work, enabling us to visualize the therapeutic process and precisely regulate treatment outcomes, which is the unremitting pursuit of precision and personalized medicine. Here, we report self-immolative photosensitizers by adopting a strategy of light-manipulated oxidative cleavage of CC bonds that can generate a burst of reactive oxygen species, to cleave to release self-reported red-emitting products and trigger nonapoptotic cell oncosis. Strong electron-withdrawing groups are found to effectively suppress the CC bond cleavage and phototoxicity via studying the structure–activity relationship, allowing us to elaborate NG1–NG5 that could temporarily inactivate the photosensitizer and quench the fluorescence by different glutathione (GSH)-responsive groups. Thereinto, NG2 with 2-cyano-4-nitrobenzene-1-sulfonyl group displays excellent GSH responsiveness than the other four. Surprisingly, NG2 shows better reactivity with GSH in weakly acidic condition, which inspires the application in weakly acidic tumor microenvironment where GSH elevates. To this end, we further synthesize NG-cRGD by anchoring integrin αvβ3 binding cyclic pentapeptide (cRGD) for tumor targeting. In A549 xenografted tumor mice, NG-cRGD successfully deprotects to restore near-infrared fluorescence because of elevated GSH in tumor site, which is subsequently cleaved upon light irradiation releasing red-emitting products to report photosensitizer working, while effectively ablating tumors via triggered oncosis. The advanced self-immolative organic photosensitizer may accelerate the development of self-reported phototheranostics in future precision oncology.

show abstract

“…Another investigation discovered that Ki-67 expression levels were markedly elevated in gastric cancer tissues compared to adjacent tissues. Moreover, a significant positive correlation was observed between Ki-67 expression and tumor infiltration, lymph node metastasis, and staging in gastric cancer cases [27]. In this study, pathological pattern, histological grade, clinical stage, invasiveness, and lymph node metastasis were related to the positive expression rate of Ki-67 and PFN1.…”

Section: Discussionsupporting

confidence: 53%

Correlation between Ki-67 or Profilin-1 Expression Levels, Clinicopathological Characteristics and Postoperative Prognosis in Patients with Bladder Cancer

2024

Ann Ital Chir

View full text Add to dashboard Cite

Background: Bladder cancer is the most common malignancy of the urinary system, and the search for new and reliable biomarkers has important clinical significance for the personalized treatment of bladder cancer. This study aims to explore the correlation between nuclear proliferation antigen (Ki-67) or Profilin-1 (PFN1) levels, clinicopathological characteristics, and postoperative prognosis in patients with bladder cancer. Methods: Patients with bladder cancer who underwent transurethral resection of bladder cancer tumor in The Fourth Affiliated Hospital of Soochow University, hospital from January 2019 to January 2021 were selected as the study group (n = 60), and patients with benign lesions of bladder cancer during the same period were selected as the control group (n = 60). The expression of Ki-67 and PFN1 in tumor and bladder tissues of the two groups was analyzed. Ki-67 recorded the patient's pathological parameters and calculated the patient's postoperative prognosis. The correlation between Ki-67 and PFN1 expression levels, pathological parameters, and postoperative prognosis was analyzed. Results: The positive expression rates of Ki-67 and PFN1 in the study group were 63.33% and 73.33%, respectively, which were significantly higher than the positive expression rates in the control group (χ2 = 14.803, 17.757, p < 0.001). The positive expression rates of Ki-67 and PFN1 were related to histological grade, clinical stage, infiltration, and lymph node metastasis, and the differences were statistically significant (p < 0.05). Bladder cancer patients with non muscle-invasive bladder cancer (NMIBC), high-grade histological grade, Ta~T1 clinical stage, invasive, and lymph node metastasis have a higher Ki-67 positive expression rate than bladder cancer patients with muscle-invasive bladder cancer (MIBC), low-grade histological grade, T2~T4, non-invasive, and no lymph node metastasis. The high expression level of Ki-67 has little relationship with gender, age, tumor diameter, and vascular invasion (p > 0.05). The survival time and three-year survival rate of the Ki-67 positive expression group were significantly lower than those of the Ki-67 negative expression group (p < 0.05). The survival time and three-year survival rate of the PFN1 positive expression group were significantly lower than those of the PFN1 negative expression group (p < 0.05). Conclusion: The positive expression rates of Ki-67 and PFN1 in bladder tumor tissue are significantly higher than those in bladder tissue, and pathological pattern, histological grade, clinical stage, infiltration, and lymph node metastasis are related to the positive expression rates of Ki-67 and PFN1, and different genders, ages, tumors diameter and vascular invasion are not related to the positive expression rates of Ki-67 and PFN1. The survival time and three-year survival rates of bladder cancer patients with Ki-67 positive and PFN1 positive expression are shorter.

show abstract

Ki67 for evaluating the prognosis of gastrointestinal stromal tumors: A systematic review and meta‑analysis

Cited by 13 publications

References 55 publications

The relationship between Ki-67 expression and imaging signs and pathological features in GISTs

The relationship between Ki-67 expression and imaging signs and pathological features in GISTs

Self-Immolative Photosensitizers for Self-Reported Cancer Phototheranostics

Correlation between Ki-67 or Profilin-1 Expression Levels, Clinicopathological Characteristics and Postoperative Prognosis in Patients with Bladder Cancer

Contact Info

Product

Resources

About